DEMETHYLATION FOR TREATMENT OF EYE DISEASE Russian patent published in 2023 - IPC A61K9/00 A61K31/706 A61K45/00 A61K48/00 A61P27/02 

FIELD: medicine; ophthalmology.

SUBSTANCE: group of inventions is intended for the treatment, alleviation or prevention of age-related eye disease or pathology. A method of treating, alleviating, or preventing an age-related eye disease or pathology comprises administering to a subject in need of treatment an effective amount of at least one demethylating agent wherein the demethylating agent is decitabine. Also the methods of treating, alleviating or preventing age-related eye disease and pathology are provided, the said methods include increasing the level of the ELOVL2 enzyme in the eye and/or the level of 22:6 (n-3) docosahexaenoic acid (DHA) and 22:5 (n-6) docosapentaenoic acid (DPC) in the eye by introducing an effective amount of mRNA encoding ELOVL2 into the eye or gene therapy using an ELOVL2 expression vector. In another embodiment, a method is provided comprising selecting a patient in need of treatment for an age-related eye disease and administering to the patient's eye an effective amount of decitabine and/or an mRNA encoding ELOVL2 and/or an ELOVL2 expression vector, thereby curing the age-related disease. Also the following are disclosed: the methods involving the use of decitabine or an mRNA encoding ELOVL2 or an ELOVL2 expression vector in the treatment of age-related eye disease. Another embodiment is a method of the treatment of age-related eye diseases, including intravitreal administration of a preparation containing decitabine.

EFFECT: use of the group of inventions provides effective treatment, alleviation or prevention of age-related eye disease or pathology.

33 cl, 13 dwg, 2 tbl, 3 ex